Vandetanib is the first targeted medication specifically approved by the FDA for the treatment of MTC, acting not only on epidermal growth factor receptor (EGFR), VEGFR, and RET in cancer cells but also inhibiting other TK and serine/threonine kinases and possessing anti-angiogenesis properties. The gene discussed is MARK2; the disease is medullary thyroid gland carcinoma.